Anti-hPD-L1-mIgG1

InvivoGen Kontakt z doradcą
Human PD-L1 antibody - Mouse IgG1
Anti-hPD-L1-mIgG1

Anti-hPD-L1-mIgG1 features a variable region equivalent to that of Atezolizumab, a therapeutic monoclonal antibody (mAb) that targets PD-L1, blocking the interaction with its receptor PD-1. Atezolizumab (formerly known as MPDL3280A) is a fully-humanized IgG1 mAb with a modified Fc region designed to limit antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [1, 2]. It contains an N298A mutation that eliminates its ability to bind to human Fcγ receptors. In contrast to nivolumab, a therapeutic mAb that targets only human PD-1, Atezolizumab targets both human and mouse PD-L1. 

To enable studies in mice,  InvivoGen's Anti-hPD-L1-mIgG1 contains the constant region of mouse IgG1; an isotype exhibiting low CDC and no ADCC. Anti-hPD-L1-mIgG1 was generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography with protein G.

Anti-hPD-L1-mIgG1 InvivoFit™ is specifically designed for mouse studies:

  • Contains a mouse IgG1 Fc domain to prevent ADAs (anti-drug-antibodies)
  • Guaranteed sterile
  • Endotoxin level
  • Low aggregation, < 5%
  • No preservative
  • Binding validated by flow cytometry using EL4 cells expressing membrane-bound mouse PD-L1

The terms “Atezolizumab” and “MPDL3280A” are only used as references. Anti-hPD-L1-mIgG1 is not a pharmaceutical biosimilar of Atezolizumab. It has not been developed nor approved by Atezolizumab owner(s), and is not intended for any therapeutic or diagnostic use in humans or animals.

References:

  1. Spigel D. et al., 2013. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [ASCO abstract 8008]. J Clin Oncol. 31(15)(suppl).
  2. Herbst RS. et al., 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515(7528):563-7.

Podobne produkty

Anti-hIFN-α7-IgG

Anti-hIFN-α7-IgG

InvivoGen
Więcej
Anti-hPD1-Pem-hIgA2

Anti-hPD1-Pem-hIgA2

InvivoGen
Więcej
Anti-hEGFR-hIgG4 (S228P)

Anti-hEGFR-hIgG4 (S228P)

InvivoGen
Więcej